These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 20192224)
1. Fragment-based deconstruction of Bcl-xL inhibitors. Barelier S; Pons J; Marcillat O; Lancelin JM; Krimm I J Med Chem; 2010 Mar; 53(6):2577-88. PubMed ID: 20192224 [TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and computational studies of inhibitors of Bcl-XL. Park CM; Oie T; Petros AM; Zhang H; Nimmer PM; Henry RF; Elmore SW J Am Chem Soc; 2006 Dec; 128(50):16206-12. PubMed ID: 17165773 [TBL] [Abstract][Full Text] [Related]
3. Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis. Petros AM; Dinges J; Augeri DJ; Baumeister SA; Betebenner DA; Bures MG; Elmore SW; Hajduk PJ; Joseph MK; Landis SK; Nettesheim DG; Rosenberg SH; Shen W; Thomas S; Wang X; Zanze I; Zhang H; Fesik SW J Med Chem; 2006 Jan; 49(2):656-63. PubMed ID: 16420051 [TBL] [Abstract][Full Text] [Related]
4. Ligand specificity in fragment-based drug design. Barelier S; Pons J; Gehring K; Lancelin JM; Krimm I J Med Chem; 2010 Jul; 53(14):5256-66. PubMed ID: 20575554 [TBL] [Abstract][Full Text] [Related]
5. (alpha/beta+alpha)-peptide antagonists of BH3 domain/Bcl-x(L) recognition: toward general strategies for foldamer-based inhibition of protein-protein interactions. Sadowsky JD; Fairlie WD; Hadley EB; Lee HS; Umezawa N; Nikolovska-Coleska Z; Wang S; Huang DC; Tomita Y; Gellman SH J Am Chem Soc; 2007 Jan; 129(1):139-54. PubMed ID: 17199293 [TBL] [Abstract][Full Text] [Related]
6. Design and implementation of an ribonucleic acid (RNA) directed fragment library. Bodoor K; Boyapati V; Gopu V; Boisdore M; Allam K; Miller J; Treleaven WD; Weldeghiorghis T; Aboul-ela F J Med Chem; 2009 Jun; 52(12):3753-61. PubMed ID: 19445516 [TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and interaction study of quinazoline-2(1H)-thione derivatives as novel potential Bcl-xL inhibitors. Feng Y; Ding X; Chen T; Chen L; Liu F; Jia X; Luo X; Shen X; Chen K; Jiang H; Wang H; Liu H; Liu D J Med Chem; 2010 May; 53(9):3465-79. PubMed ID: 20405848 [TBL] [Abstract][Full Text] [Related]
8. Advancing fragment binders to lead-like compounds using ligand and protein-based NMR spectroscopy. Maurer T Methods Enzymol; 2011; 493():469-85. PubMed ID: 21371602 [TBL] [Abstract][Full Text] [Related]
9. A new assay for the discovery of Bcl-XL inhibitors. Pisoni C; Cimoli G; Resconi A; Losi D; Lorenzetti R; Parodi S; Carrano L Farmaco; 2005; 60(11-12):938-43. PubMed ID: 16054143 [TBL] [Abstract][Full Text] [Related]
10. Targeting the BH3 domain mediated protein-protein interaction of Bcl-xL through virtual screening. Mukherjee P; Desai P; Zhou YD; Avery M J Chem Inf Model; 2010 May; 50(5):906-23. PubMed ID: 20392095 [TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationship studies of phenanthridine-based Bcl-XL inhibitors. Bernardo PH; Wan KF; Sivaraman T; Xu J; Moore FK; Hung AW; Mok HY; Yu VC; Chai CL J Med Chem; 2008 Nov; 51(21):6699-710. PubMed ID: 18925736 [TBL] [Abstract][Full Text] [Related]
12. Structure of an allosteric inhibitor of LFA-1 bound to the I-domain studied by crystallography, NMR, and calorimetry. Crump MP; Ceska TA; Spyracopoulos L; Henry A; Archibald SC; Alexander R; Taylor RJ; Findlow SC; O'Connell J; Robinson MK; Shock A Biochemistry; 2004 Mar; 43(9):2394-404. PubMed ID: 14992576 [TBL] [Abstract][Full Text] [Related]
13. Ligand mapping on protein surfaces by the 3D-RISM theory: toward computational fragment-based drug design. Imai T; Oda K; Kovalenko A; Hirata F; Kidera A J Am Chem Soc; 2009 Sep; 131(34):12430-40. PubMed ID: 19655800 [TBL] [Abstract][Full Text] [Related]
14. Custom chemical microarray production and affinity fingerprinting for the S1 pocket of factor VIIa. Dickopf S; Frank M; Junker HD; Maier S; Metz G; Ottleben H; Rau H; Schellhaas N; Schmidt K; Sekul R; Vanier C; Vetter D; Czech J; Lorenz M; Matter H; Schudok M; Schreuder H; Will DW; Nestler HP Anal Biochem; 2004 Dec; 335(1):50-7. PubMed ID: 15519570 [TBL] [Abstract][Full Text] [Related]
15. Rationale for Bcl-xL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies. Petros AM; Nettesheim DG; Wang Y; Olejniczak ET; Meadows RP; Mack J; Swift K; Matayoshi ED; Zhang H; Thompson CB; Fesik SW Protein Sci; 2000 Dec; 9(12):2528-34. PubMed ID: 11206074 [TBL] [Abstract][Full Text] [Related]
16. Ligand specificity, privileged substructures and protein druggability from fragment-based screening. Barelier S; Krimm I Curr Opin Chem Biol; 2011 Aug; 15(4):469-74. PubMed ID: 21411360 [TBL] [Abstract][Full Text] [Related]
17. Identification of lead compounds as antagonists of protein Bcl-xL with a diversity-oriented multidisciplinary approach. Di Micco S; Vitale R; Pellecchia M; Rega MF; Riva R; Basso A; Bifulco G J Med Chem; 2009 Dec; 52(23):7856-67. PubMed ID: 19852471 [TBL] [Abstract][Full Text] [Related]
18. Relaxation of the rigid backbone of an oligoamide-foldamer-based α-helix mimetic: identification of potent Bcl-xL inhibitors. Yap JL; Cao X; Vanommeslaeghe K; Jung KY; Peddaboina C; Wilder PT; Nan A; MacKerell AD; Smythe WR; Fletcher S Org Biomol Chem; 2012 Apr; 10(15):2928-33. PubMed ID: 22395339 [TBL] [Abstract][Full Text] [Related]
19. Chelerythrine and sanguinarine dock at distinct sites on BclXL that are not the classic BH3 binding cleft. Zhang YH; Bhunia A; Wan KF; Lee MC; Chan SL; Yu VC; Mok YK J Mol Biol; 2006 Dec; 364(3):536-49. PubMed ID: 17011577 [TBL] [Abstract][Full Text] [Related]
20. A small molecule-regulated guanine nucleotide exchange factor. Goreshnik I; Maly DJ J Am Chem Soc; 2010 Jan; 132(3):938-40. PubMed ID: 20020680 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]